EMA/PE/0000242035 - paediatric investigation plan
puxitatug samrotecan
PIPHuman
Icelandic is available via eTranslation, the European Commission's machine translation service.
Translate to Icelandic | Important information about machine translation
Key facts
- Active substance
- puxitatug samrotecan
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- EMA/PE/0000242035
- PIP number
- EMA/PE/0000242035
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of biliary tract cancer
- Treatment of endometrial cancer
- Treatment of lung cancer
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date
- Compliance check done
- Nei